Go Premium

Notifications

TipRanks

Notifications

Tag: EVH

Total 146 Posts

Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Evolent Health (EVH) and BioMarin Pharmaceutical (BMRN)

April 25, 2024

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Biogen (BIIB – Research Report), Evolent Health (EVH – Research Report) and BioMarin Pharmaceutical (BMRN – Research Report).

Biogen (BIIB)

RBC Capital analyst Brian Abrahams maintained a Buy rating on Biogen yesterday and set a price target of $317.00. The company’s shares closed last Wednesday at $201.99, close to its 52-week low of $189.44.

According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 6.5% and a 47.0% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Neumora Therapeutics, Inc., Intra-Cellular Therapies, and Karyopharm Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $283.52 average price target, a 42.5% upside from current levels. In a report released today, Canaccord Genuity also maintained a Buy rating on the stock with a $308.00 price target.

See the top stocks recommended by analysts >>

Evolent Health (EVH)

In a report released yesterday, Sean Dodge from RBC Capital maintained a Buy rating on Evolent Health, with a price target of $42.00. The company’s shares closed last Wednesday at $29.26.

According to TipRanks.com, Dodge is ranked 0 out of 5 stars with an average return of -7.5% and a 38.5% success rate. Dodge covers the Healthcare sector, focusing on stocks such as Healthcare Services, Privia Health Group, and Avid Bioservices.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Evolent Health with a $45.90 average price target, which is a 52.7% upside from current levels. In a report issued on April 22, Citi also initiated coverage with a Buy rating on the stock with a $40.00 price target.

BioMarin Pharmaceutical (BMRN)

RBC Capital analyst Luca Issi maintained a Hold rating on BioMarin Pharmaceutical yesterday and set a price target of $100.00. The company’s shares closed last Wednesday at $91.20.

According to TipRanks.com, Issi is ranked 0 out of 5 stars with an average return of -25.0% and a 19.6% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Ultragenyx Pharmaceutical, and Lexeo Therapeutics, Inc.

BioMarin Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $111.24.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BIIB:

אנליסט מ-Citi, דניאל גרוסלייט, התחיל לכסות את Evolent Health עם המלצה לקנייה וקבע מחיר יעד של 40 דולר

April 22, 2024

Evolent Health סוף סוף מצאה את הקצב שלה לאחר שניסתה מודלים עסקיים שונים, ומצאה מקום טוב בשוק לטיפול מבוסס ערך שמתמקד בשירותים רפואיים מיוחדים, גרוסלייט מסביר למשקיעים בהערת מחקר. החברה

Analysts’ Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)

April 17, 2024

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Evolent Health (EVH – Research Report), Nurix Therapeutics (NRIX – Research Report) and Legend Biotech (LEGN – Research Report) with bullish sentiments.

Evolent Health (EVH)

In a report released today, Jessica Tassan from Piper Sandler maintained a Buy rating on Evolent Health, with a price target of $51.00. The company’s shares closed last Tuesday at $30.16.

According to TipRanks.com, Tassan is a 1-star analyst with an average return of -2.1% and a 41.2% success rate. Tassan covers the Healthcare sector, focusing on stocks such as Alignment Healthcare, Privia Health Group, and Health Catalyst.

Evolent Health has an analyst consensus of Strong Buy, with a price target consensus of $46.56, which is a 54.9% upside from current levels. In a report issued on April 5, RBC Capital also maintained a Buy rating on the stock with a $42.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Nurix Therapeutics (NRIX)

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Nurix Therapeutics today and set a price target of $35.00. The company’s shares closed last Tuesday at $14.65.

According to TipRanks.com, Catanzaro is a 4-star analyst with an average return of 9.7% and a 41.2% success rate. Catanzaro covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Black Diamond Therapeutics, and Acrivon Therapeutics, Inc.

Currently, the analyst consensus on Nurix Therapeutics is a Strong Buy with an average price target of $25.09, a 62.9% upside from current levels. In a report issued on April 2, Robert W. Baird also maintained a Buy rating on the stock with a $24.00 price target.

Legend Biotech (LEGN)

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Legend Biotech today and set a price target of $90.00. The company’s shares closed last Tuesday at $50.12.

According to TipRanks.com, Tenthoff is a 1-star analyst with an average return of -1.4% and a 33.2% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Milestone Pharmaceuticals, and Arvinas Holding Company.

Currently, the analyst consensus on Legend Biotech is a Strong Buy with an average price target of $86.58, implying a 73.2% upside from current levels. In a report issued on April 3, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $82.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on EVH:

Analysts Offer Insights on Healthcare Companies: Bausch Health Companies (BHC), Walgreens Boots Alliance (WBA) and Evolent Health (EVH)

April 15, 2024

Analysts fell to the sidelines weighing in on Bausch Health Companies (BHC – Research Report), Walgreens Boots Alliance (WBA – Research Report) and Evolent Health (EVH – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Bausch Health Companies (BHC)

Truist Financial analyst Les Sulewski maintained a Hold rating on Bausch Health Companies today. The company’s shares closed last Friday at $8.76.

According to TipRanks.com, Sulewski is a 4-star analyst with an average return of 19.3% and a 67.6% success rate. Sulewski covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Pacira Pharmaceuticals, and Amneal Pharmaceuticals.

Bausch Health Companies has an analyst consensus of Hold, with a price target consensus of $10.80, representing a 22.2% upside. In a report issued on April 5, RBC Capital also assigned a Hold rating to the stock with a $12.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Walgreens Boots Alliance (WBA)

In a report released today, David S Macdonald from Truist Financial maintained a Hold rating on Walgreens Boots Alliance, with a price target of $20.00. The company’s shares closed last Friday at $17.85, close to its 52-week low of $17.70.

According to TipRanks.com, Macdonald is a 5-star analyst with an average return of 12.6% and a 63.9% success rate. Macdonald covers the Healthcare sector, focusing on stocks such as Pediatrix Medical Group, Option Care Health, and Quest Diagnostics.

Walgreens Boots Alliance has an analyst consensus of Hold, with a price target consensus of $23.36, representing a 30.2% upside. In a report issued on April 3, Deutsche Bank also maintained a Hold rating on the stock with a $22.00 price target.

Evolent Health (EVH)

In a report released today, Jailendra Singh from Truist Financial maintained a Hold rating on Evolent Health. The company’s shares closed last Friday at $30.13.

According to TipRanks.com, Singh is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -13.9% and a 32.4% success rate. Singh covers the Healthcare sector, focusing on stocks such as Privia Health Group, Hims & Hers Health, and GoodRx Holdings.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Evolent Health with a $46.56 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BHC: